WO2011106951A1 - 左旋氨氯地平复方药物组合物 - Google Patents

左旋氨氯地平复方药物组合物 Download PDF

Info

Publication number
WO2011106951A1
WO2011106951A1 PCT/CN2010/074004 CN2010074004W WO2011106951A1 WO 2011106951 A1 WO2011106951 A1 WO 2011106951A1 CN 2010074004 W CN2010074004 W CN 2010074004W WO 2011106951 A1 WO2011106951 A1 WO 2011106951A1
Authority
WO
WIPO (PCT)
Prior art keywords
levamlodipine
pharmaceutical composition
chlorthalidone
levoamlodipine
compound pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2010/074004
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
杨彦玲
薛传校
张喜田
许威
张严
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shihuida Pharmaceutical Group Jilin Ltd
Original Assignee
Shihuida Pharmaceutical Group Jilin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shihuida Pharmaceutical Group Jilin Ltd filed Critical Shihuida Pharmaceutical Group Jilin Ltd
Priority to EP10846870.3A priority Critical patent/EP2543373A4/en
Priority to CA2754839A priority patent/CA2754839C/en
Priority to US13/264,829 priority patent/US20120041035A1/en
Priority to JP2012502443A priority patent/JP2012522024A/ja
Publication of WO2011106951A1 publication Critical patent/WO2011106951A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the invention belongs to the field of pharmacy, in particular to a compound pharmaceutical composition of levamlodipine. Background technique
  • Hypertension is a clinical syndrome characterized by increased systemic systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) and is one of the most common cardiovascular diseases.
  • SBP systemic systolic blood pressure
  • DBP diastolic blood pressure
  • Table 4 is a comparison table of 1000 tablets of levamlodipine and chlorthalidone compound tablets.
  • Microcrystalline cellulose (g) 25.00 25.00 12.50

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
PCT/CN2010/074004 2010-03-03 2010-06-17 左旋氨氯地平复方药物组合物 Ceased WO2011106951A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP10846870.3A EP2543373A4 (en) 2010-03-03 2010-06-17 PHARMACEUTICAL COMPOSITION COMPOSITION OF LEVOAMLODIPIN
CA2754839A CA2754839C (en) 2010-03-03 2010-06-17 Pharmaceutical composition comprising levamlodipine and chlorthalidone
US13/264,829 US20120041035A1 (en) 2010-03-03 2010-06-17 Levamlodipine compound pharmaceutical composition
JP2012502443A JP2012522024A (ja) 2010-03-03 2010-06-17 左旋性アムロジピン複合薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010101168675 2010-03-03
CN2010101168675A CN101780079B (zh) 2010-03-03 2010-03-03 左旋氨氯地平复方药物组合物

Publications (1)

Publication Number Publication Date
WO2011106951A1 true WO2011106951A1 (zh) 2011-09-09

Family

ID=42520307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/074004 Ceased WO2011106951A1 (zh) 2010-03-03 2010-06-17 左旋氨氯地平复方药物组合物

Country Status (6)

Country Link
US (1) US20120041035A1 (https=)
EP (1) EP2543373A4 (https=)
JP (1) JP2012522024A (https=)
CN (1) CN101780079B (https=)
CA (1) CA2754839C (https=)
WO (1) WO2011106951A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110755429A (zh) * 2018-07-26 2020-02-07 北京市石景山区高血压联盟研究所 一种复方降压药组合物、其制剂及其用途
CN111789843A (zh) 2019-04-08 2020-10-20 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物
CN110372575A (zh) * 2019-07-10 2019-10-25 复旦大学 一种二氢吡啶钙拮抗剂共晶体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101472557A (zh) * 2006-06-16 2009-07-01 Lts罗曼治疗方法有限公司 抗高血压药物组合物干胶片

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
CN1960712B (zh) * 2004-05-21 2011-04-20 阿库-伯雷克技术公司 包含多个片段的刻痕药片
US7625940B2 (en) * 2005-07-01 2009-12-01 Accu-Break Technologies, Inc. Method of treating hypertension with a very low dose of chlorthalidone
US20070237815A1 (en) * 2006-04-06 2007-10-11 Lawrence Solomon Dosage forms and methods comprising amlodipine and chlorthalidone
CN101564536B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物缓控释制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101472557A (zh) * 2006-06-16 2009-07-01 Lts罗曼治疗方法有限公司 抗高血压药物组合物干胶片

Also Published As

Publication number Publication date
JP2012522024A (ja) 2012-09-20
CA2754839C (en) 2013-12-10
CN101780079B (zh) 2011-10-05
US20120041035A1 (en) 2012-02-16
EP2543373A1 (en) 2013-01-09
CA2754839A1 (en) 2011-09-09
EP2543373A4 (en) 2013-07-31
CN101780079A (zh) 2010-07-21

Similar Documents

Publication Publication Date Title
BR112013025222B1 (pt) Composição farmacêutica anti-hipertensiva e uso da mesma
WO2011106951A1 (zh) 左旋氨氯地平复方药物组合物
CN101766582B (zh) 一种苯磺酸左旋氨氯地平的片剂及其制备方法
AU2010276461B2 (en) Pharmaceutical composition of levamlodipine or pharmaceutically acceptable salt thereof and beta receptor blocking agent, and use thereof
KR101303841B1 (ko) 고혈압 및 대사증후군 질환 치료용 약학적 조성물 및 이의 용도
WO2013152641A1 (zh) 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
KR20080097787A (ko) 로라타딘 및 슈도에페드린을 함유하는 제어 방출 다층정
CN110041244B (zh) 多奈哌齐与缬沙坦共无定型合物及制备方法和其组合物与用途
JP5982715B2 (ja) 抗高血圧薬組成物
CN101766581B (zh) 一种群孔释放的盐酸地尔硫卓择时控释片及其制备方法
CN111388439A (zh) 一种含有甲磺酸多沙唑嗪速释与缓释的片剂及其制备方法
CN110755397A (zh) 一种复方降压药物片剂及其用途
CN101884634A (zh) 一种治疗心血管疾病的组合物
WO2011137601A1 (zh) 左旋氨氯地平复方药物制剂
JPH01283224A (ja) 抗高血圧の組み合わせ調合物
CA2727957A1 (en) Pharmaceutical composition comprising levamlodipine and indapamide
UA146879U (uk) Фармацевтична композиція
CN103040817A (zh) 一种用于治疗高血压的复方制剂
CN102349904A (zh) 一种全新的口服固体药用组合物及其制备方法
CN111789843A (zh) 含氨氯地平、氯噻酮和阿米洛利的药物组合物
Rahman In Vitro Kinetic Studies of Combined Amlodipine (5mg) and Atenolol (50mg) Tablet Dosage Form: A Comparative Study with Similar Market Products Available in Bangladesh
KR20090090748A (ko) 조합 성분을 함유한 혈관질환 예방치료제
EP2374457A1 (en) Antihypertensive pharmaceutical composition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2754839

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012502443

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010846870

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 7474/CHENP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 13264829

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10846870

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE